Hematologist
CION Cancer Clinics
AML subtypes: what the classification means | CION Cancer Clinics
An AML subtype tells you which kind of acute myeloid leukaemia you have. Current systems name it mainly by the gene and chromosome changes in the blast cells, while older reports use FAB labels from M0 to M7. The subtype guides treatment and how the team judges the chance of relapse. This page explains the main families, how the label is worked out, and what it cannot tell you. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What does an AML subtype actually mean?
- Which groups of AML will your haematologist talk about?
- How is the subtype worked out?
- What do the old FAB labels like M3 or M5 mean?
- What do families misunderstand about AML subtypes?
- What do common subtype phrases mean for the plan?
- What does your subtype change, and what can it not tell you?
- Common questions about AML subtypes
The short answer
What does an AML subtype actually mean?
An AML subtype is the name for which kind of AML you have. Today it is decided mainly by the gene and chromosome changes inside the blast cells, and that name helps the team choose treatment and judge how likely the leukaemia is to come back.
Why there are two naming systems on reports
Older reports use the FAB system, which sorts AML into groups from M0 to M7 by how the cells look under the microscope. Newer reports follow the World Health Organization (WHO) classification or the International Consensus Classification (ICC). Both were updated in 2022 and both put the genetic change first. You may see either, or an old and a new name side by side.
Why the name comes in stages
The first report after a marrow test often says only "acute myeloid leukaemia". The full subtype follows when chromosome and gene results arrive, which can take one to three weeks. A report that changes its label later has not made a mistake. It has more information.
Why the family should keep every report
Each test result adds a piece to the name. If you move between hospitals, or ask for a second opinion, the new team will need all of them: the smear, the marrow report, flow cytometry, karyotype and the gene panel. Keep copies together in one folder, in date order, and carry it to every visit.
Classification rules are technical and updated from time to time. Your haematologist will tell you which name applies to you.The main families
Which groups of AML will your haematologist talk about?
Current systems sort AML into a handful of broad families. The exact wording on your report may differ slightly.
AML with a defining genetic change
A specific change in a gene or chromosome defines the leukaemia. Examples include NPM1 mutation, CBFB-MYH11 and RUNX1-RUNX1T1. Several of these respond well to standard chemotherapy.
Acute promyelocytic leukaemia (PML-RARA) belongs here and is treated very differently.AML related to myelodysplasia
The leukaemia carries changes linked with earlier marrow failure, or followed a known myelodysplastic syndrome. It tends to be harder to treat and is more common in older adults.
AML after earlier cancer treatment
Sometimes called therapy-related AML. It follows chemotherapy or radiotherapy given for another illness, often years before. The report may add this as a label to another subtype.
AML defined by how it looks
When no defining genetic change is found, the leukaemia is named by which cell type the blasts resemble, much like the old FAB groups.
Words you may see
- Minimal or no maturation
- Myelomonocytic or monocytic
- Erythroid or megakaryoblastic
Not sure whether this applies to you?
Ask an oncologistBehind the label
How is the subtype worked out?
Looking at the cells
The pathologist studies blood and marrow slides, counts the blasts and notes how they look. This gives a first answer within a day or two.
Flow cytometry
A machine reads markers on the surface of the blasts. It confirms the cells are myeloid, not lymphoid, and hints at which cell family they resemble.
Chromosome tests
Karyotype and FISH look for missing, extra or swapped pieces of chromosomes. FISH can give some key answers within days.
Gene tests
PCR and gene panels look for changes such as FLT3, NPM1, CEBPA, IDH1, IDH2 and TP53. Together with the chromosome results they give the final subtype.
On older reports
What do the old FAB labels like M3 or M5 mean?
- M0, M1, M2
- AML with blasts that show little, some or more signs of growing up. These labels are now mostly replaced by genetic names.
- M3
- Acute promyelocytic leukaemia (APL). Still widely used, and a label that should always trigger urgent treatment.
- M4 and M5
- Myelomonocytic and monocytic AML. Blasts resemble monocytes and more often cause swollen gums or skin lumps.
- M6
- Erythroid leukaemia, where blasts resemble early red cells. It is rare and now classed differently.
- M7
- Megakaryoblastic leukaemia, from cells that make platelets. Rare in adults.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do families misunderstand about AML subtypes?
"A higher M number means a worse cancer."
The numbers are not a scale of severity. They only describe which cell the blasts resemble. M3, for example, is dangerous early on, yet it often responds very well once the right treatment starts.
"Treatment should wait until every result is back."
For most kinds of AML, the team starts when it is safe and adjusts as results arrive. For APL, treatment starts on suspicion, before the gene test confirms it, because bleeding risk is highest in the first days.
"Our subtype was changed, so the first lab was wrong."
Usually the name changed because gene results came in. That is how the process is meant to work. Ask your team to explain what the new name adds.
"If we know the subtype, we know the survival."
The subtype is only one part of the picture. Age, fitness and how the leukaemia responds to treatment matter just as much.
Side by side
What do common subtype phrases mean for the plan?
If the report says
What the team usually considers
APL, M3 or PML-RARA
Urgent start with ATRA-based treatment and close watch for bleeding
NPM1 mutated, with no FLT3-ITD
Often responds well to standard chemotherapy
Core binding factor, such as inv(16) or t(8;21)
Often responds well to chemotherapy; a transplant is less often needed early
Myelodysplasia-related or TP53 change
Harder to treat; transplant or clinical trials often discussed
Therapy-related
Earlier treatment, heart health and fitness weigh heavily in the plan
Being straight with you
What does your subtype change, and what can it not tell you?
Your subtype changes three things: which medicines are used, whether a transplant is likely to be discussed, and how closely the team watches for the leukaemia coming back. It does not decide everything on its own.
Why APL is handled as a separate emergency
Acute promyelocytic leukaemia can cause sudden, serious bleeding. It is treated with a vitamin A-based medicine called ATRA, often with arsenic trioxide, rather than standard AML chemotherapy. If APL is suspected, treatment usually starts the same day. It is one of the kinds of AML that responds well when treated quickly.
Who the subtype label helps less
For some older or less fit adults, the plan is shaped more by what the body can take than by the exact subtype. A lower-intensity approach may suit them whatever the label says.
What this page cannot tell you
It cannot read your own report. Classification rules have exceptions and details that only a haematologist with every result can apply. Ask them to write down your full subtype and what it means for your plan.
Questions we are asked
Common questions about AML subtypes
Which AML subtype is the most common?
In adults, AML with an NPM1 mutation is one of the most frequent genetic subtypes. AML related to myelodysplasia is common in older adults. The mix differs by age and by country, so the most useful question is not which is common but what your own report shows.
Is APL a type of AML?
Yes. Acute promyelocytic leukaemia is a subtype of AML, once called M3. It is treated very differently from other kinds and needs urgent care because of bleeding risk. If you see APL, M3 or PML-RARA on a report, contact the haematology team straight away.
How long do the subtype tests take?
Slide and flow cytometry results usually come within a day or two. Some FISH and PCR tests come within days. A full karyotype and gene panel can take one to three weeks. Your team will usually start treatment before the last result, and adjust if needed.
Does the subtype decide if a transplant is needed?
It is one of the main inputs. Subtypes with a higher chance of relapse make a transplant in first remission more likely to be discussed. Response to the first treatment, fitness and donor availability also count. Ask your team early, so donor searching is not delayed.
What does "AML with myelodysplasia-related changes" mean?
It means the leukaemia shows gene or chromosome changes, or a history, linked with an earlier marrow disorder called myelodysplastic syndrome. It tends to respond less well to standard chemotherapy, and some newer combination treatments are designed with this group in mind.
Can the subtype change later?
The original subtype stays the same. If the leukaemia comes back, it can pick up new gene changes, so tests are often repeated at relapse. That can open different treatment options, such as a targeted medicine that did not apply the first time.
Is the subtype the same as the risk group?
No, though they are linked. The subtype names the kind of AML. The risk group, often favourable, intermediate or adverse, uses the gene and chromosome results to estimate how likely standard treatment is to keep the leukaemia away. Your report may carry both.
Should we get the marrow sample tested at a second lab?
A second review of slides or results can be reasonable, especially if the report is unclear. It should not delay treatment that your haematologist says is urgent. Ask whether the sample can be shared quickly rather than repeating the marrow test.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — How Is Acute Myeloid Leukemia Classified?
- National Cancer Institute — Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version
- Leukemia & Lymphoma Society — Acute Myeloid Leukemia (AML)
- Cancer Research UK — Acute myeloid leukaemia (AML)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
FLT3, NPM1 and IDH in AML: Why Mutations MatterThe gene results that define many subtypesAML Risk Groups and What They PredictHow the subtype feeds into your risk groupSecondary AML After Previous Cancer TreatmentIf AML followed earlier chemotherapy or radiotherapyAML Explained: What Happens and How FastThe basics of AML, if you are starting here
Talk to us
Unsure what your AML report says?
Share it with us. CION's haematology team will explain the subtype and what it means for the plan. One helpline serves every CION centre.